Involving Antigen-antibody Binding, Specific Binding Protein Assay Or Specific Ligand-receptor Binding Assay Patents (Class 435/7.1)
  • Patent number: 10287327
    Abstract: A series of protein A mutants having high alkali resistance, and methods of using the protein A mutants are provided. The protein A mutants have a high binding affinity for regions of immunoglobulin proteins other than the complementarity determining regions. The protein A mutants can be coupled to a solid support for immunoglobulin isolation, or conjugated to a label for immunoglobulin detection. This series of protein A mutants has high chemical stability under alkaline conditions of pH 13-14, and can also be used as chromatography ligands for purification procedures that use alkaline solutions under harsh conditions, such as Clean-In-Place (CIP). Also provided are methods of immunoglobulin separation and purification, and alkali regeneration of affinity chromatography medium that uses protein A as a ligand.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: May 14, 2019
    Assignee: Nanjingjinsirui Science & Technology Biology Corp.
    Inventors: Hong Qian, Tao Bai, Rong Hua
  • Patent number: 10288627
    Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: May 14, 2019
    Assignee: D-Gen Limited
    Inventors: Graham Stuart Jackson, John Collinge, Julie Ann Edgeworth
  • Patent number: 10281465
    Abstract: The present invention provides methods, devices, compositions (e.g., capture complexes), and kits useful for enhancing the detection of antibodies in a test sample. The methods, devices, and compositions utilize detectable Fc-binding molecules such as Protein A, Protein G, and/or an Fc-specific antibody to amplify the signal of a detected antibody in immunoassays, such as lateral flow assays.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: May 7, 2019
    Assignee: ABAXIS, INC.
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Jeremy Walker, Cristina Cuesico
  • Patent number: 10281462
    Abstract: A system comprised of an apparatus and a test device is described. The test device and the apparatus are designed to interact to determine the presence or absence of an analyte of interest in a sample placed on the test device.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: May 7, 2019
    Assignee: Quidel Corporation
    Inventors: Richard L. Egan, Michael Jon Hale, Jhobe Steadman
  • Patent number: 10272144
    Abstract: Compositions useful to induce anti-TACA immune response and kits comprising the same and methods of using the compositions to treat and prevent cancer are disclosed. Isolated human antibodies which bind to a carbohydrate mimetic peptide and methods of making the same and using the same to treat and prevent cancer are disclosed. Isolated human NK cells useful to kill tumor cells, and isolated human dendritic cells, and methods of making the same and using the same to treat and prevent cancer are disclosed.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: April 30, 2019
    Assignee: BioVentures, LLC
    Inventors: Thomas Kieber-Emmons, Anastas Pashov, Behjatolah Karbassi
  • Patent number: 10274481
    Abstract: The present invention relates to use of inhibitors of Notch signalling pathway selected from the group consisting of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, in treating and/or preventing cancers.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: April 30, 2019
    Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
    Inventors: Freddy Radtke, Rajwinder Lehal, Viktoria Reinmüller, Jieping Zhu
  • Patent number: 10272191
    Abstract: The present invention provides a filter for separating particles and/or catalyzer for particle reaction in a fluid. The device comprising array of passageways fabricated on a die wherein the passageway size is controlled by actuators. The passageway size is monitored and the actuators controlling the passageway size are activated conditionally upon the passageway size monitoring. Using movable actuators the passageway can achieve passageway size that is less then the fabrication minimal resolution. Proper locating, setting and/or activation of the actuators create passageways that can perform filtration of particles, trapping of particles and catalyzing particles reaction.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: April 30, 2019
    Inventor: David Hirshberg
  • Patent number: 10265389
    Abstract: The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: April 23, 2019
    Assignee: INTERNATIONAL INSTITUTE OF IMMUNOLOGY, INC.
    Inventors: Haruo Sugiyama, Yusuke Oji
  • Patent number: 10267788
    Abstract: A method including identifying one or more structures in adjacent sequences of one or more proteins that can be mimicked by a peptide; and assembling a peptide that mimics the one or more secondary structures. A method including assembling epitopes of linked pairs of discontiguous peptide subsequences that mimic one or more structures in sequences of a protein; and assaying antibodies against the epitopes.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: April 23, 2019
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Joseph S. Schoeniger, Peter Anderson
  • Patent number: 10267754
    Abstract: The present invention generally relates to a method of using NMR relaxation rates (R2) of water molecules as an indicator of the extent of aggregation of biopharmaceutical formulations. The biopharmaceutical can be evaluated nondestructively without the vial or container being opened or protective seal compromised (i.e., broken). The method is applicable to all biopharmaceuticals and the water signal obtained by magnetic resonance relaxometry is very strong and sensitive because water is used as the solvent and is present in high (>90%) concentrations in every biopharmaceutical formulation.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: April 23, 2019
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Yihua Bruce Yu, Marc Taraban, Yue Feng
  • Patent number: 10258700
    Abstract: Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: April 16, 2019
    Assignee: DUKE UNIVERSITY
    Inventor: Ashutosh Chilkoti
  • Patent number: 10253377
    Abstract: Systems and methods to assess the health of various microbiomes and to identity species therein are disclosed. Described assessments and identifications can inform treatment decisions if a microbiome is determined to have a less than optimal balance of bacterial species within it; the presence of one or more negative species; and/or the absence of one or more positive species.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: April 9, 2019
    Assignee: Wayne State University
    Inventors: Robert A. Akins, Jack D. Sobel
  • Patent number: 10253185
    Abstract: Disclosed herein are compounds, compositions, methods and kits for detecting pH in samples using pH-sensitive fluorescent dyes. The compounds disclosed herein are novel xanthene-derivative dyes comprising an aniline moiety with one or more electron donating groups, which dyes are for detecting pH in samples either in vitro or in vivo. Also described herein are processes for preparing said dyes for use in the disclosed compositions, methods and kits.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: April 9, 2019
    Assignee: Life Technologies Corporation
    Inventors: Kyle Gee, Upinder Singh, Aleksey Rukavishnikov, Daniel Beacham, Shih-Jung Huang, Michael Janes, Wenjun Zhou
  • Patent number: 10253363
    Abstract: The present invention includes, but is not limited to, methods, assays, and compositions for preparing libraries of nucleic acid molecules from biological samples, and for detecting and measuring the abundances of nucleic acid molecules, including RNA and DNA. The methods, assays, and compositions of the present invention provide in whole or in part for the detecting and measuring the abundances of nucleic acid molecules, and particularly but not limited to those nucleic acids that have structures that cannot be determined reliably by routine alignment to a reference sequence or concatenation of smaller sequences by matching homologous ends.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 9, 2019
    Inventor: John Welsh
  • Patent number: 10247731
    Abstract: Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the persistence and propagation of a cancer has been developed. The system of using these data to produce T cells engineered to express T cell receptors recognizing the peptide antigens is used in the production of a personalized adoptive T cell therapy for cancer that eliminates the cells capable of tumor propagation and cancer progression. The system is especially useful in the production of cancer treatments to achieve complete durable remission of cancers of epithelial origin.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: April 2, 2019
    Assignee: Verik Bio, Inc.
    Inventors: Nancy L. Parenteau, Joseph C. Laning, Janet H. Young
  • Patent number: 10242851
    Abstract: A method of mass spectrometry is disclosed that comprises predicting 1 one or more first reaction products which may result from subjecting an analyte to one or more reactions of interest, calculating 2 one or more first masses or mass to charge ratios and one or more first ion mobility values, collision cross sections or interaction cross sections of at least some first reaction product ions which may be generated from the one or more first reaction products under first conditions, and calculating one or more second masses or mass to charge ratios and one or more second ion mobility values, collision cross sections or interaction cross sections of at least some second reaction product ions which may be generated from the one or more first reaction products under second different conditions.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: March 26, 2019
    Assignee: Micromass UK Limited
    Inventors: Martin Raymond Green, Kevin Giles, Keith Richardson, Jason Lee Wildgoose
  • Patent number: 10242853
    Abstract: A method of mass spectrometry comprises ionizing a sample eluting from a separation device in order to generate a plurality of parent ions. The method further comprises generating a target list of ions, which includes a predicted mass to charge ratio, a predicted chromatographic retention or elution time, and a predicted ion mobility drift time, derived from a model. Multiple cycles of operation are then performed as the sample elutes from the separation device. Each cycle of operation includes mass filtering the parent ions so that selected ions having mass to charge ratios within a first mass to charge ratio range are onwardly transmitted to a fragmentation or reaction device. The target list is then checked and the model is updated accordingly. The first mass to charge ratio range can then be adjusted in response to the updated model.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: March 26, 2019
    Assignee: Waters Technologies Corporation
    Inventors: Scott J Geromanos, Steven J Ciavarini, Weibin Chen, Stephane Houel
  • Patent number: 10234454
    Abstract: The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: March 19, 2019
    Assignee: Macau University of Science and Technology
    Inventors: Liang Liu, Jing-Rong Wang, Weina Gao, Leefong Yau, Hao Huang, Qiong Meng, Tiantian Tong, Zhi-Hong Jiang
  • Patent number: 10233431
    Abstract: The present invention provides for a polyketide synthase (PKS) capable of synthesizing a 3-hydroxycarboxylic acid or ketone. The present invention also provides for a host cell comprising the PKS and when cultured produces the 3-hydroxycarboxylic acid or ketone.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: March 19, 2019
    Assignee: The Regents of the University of California
    Inventors: Satoshi Yuzawa, Leonard Katz, Jay D. Keasling
  • Patent number: 10233241
    Abstract: Agents that specifically bind to an opioid receptor in a conformationally specific way can be used to induce a conformational change in the receptor. Such agents have therapeutic applications and can be used in X-ray crystallography studies of the receptor. Such agents can also be used to improve drug discovery via compound screening and/or structure-based drug design.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: March 19, 2019
    Assignees: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Jan Steyaert, Toon Laeremans, Els Pardon, Brian Kobilka, Aashish Manglik
  • Patent number: 10226507
    Abstract: The present invention relates to alpha-1-microglobulin for use in the treatment of a mitochondria-related disease.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: March 12, 2019
    Assignee: A1M PHARMA AB
    Inventors: Bo Åkerstrom, Magnus Gram, Lena Rosenlöf
  • Patent number: 10228371
    Abstract: A liposomal composition comprising a sterol-modified lipid and a purified mycobacterial lipid cell wall component or analog or derivative thereof is described. The composition is useful as a lipid antigen-presenting vehicle for the detection of lipid antigen specific biomarker antibodies in antibody containing biological samples in the diagnosis of active tuberculosis. The purified lipid cell wall component is typically a purified mycolic acid or a mixture of mycolic acids from a mycobacterium that produces mycolic acids. The sterol-modified lipid is typically a phospholipid.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: March 12, 2019
    Assignee: University of Pretoria
    Inventors: Carl Baumeister, Walter Allen Shaw, Jan Adrianus Verschoor
  • Patent number: 10228372
    Abstract: A nanoplasmonic platform can be used for the detection and quantification of multiple HIV subtypes in whole blood with localized surface plasmon resonance. Among other things, this nanoplasmonic platform provides a viable way to detection and quantification of viral load at a point of care with significantly less cost, time, and laboratory resources than existing methods of detection. Although an example of HIV detection in whole blood is provided, the nanoplasmonic platform is adaptable to detect other pathogens and infectious agents or macromolecules.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: March 12, 2019
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL
    Inventors: Utkan Demirci, Fatih Inci
  • Patent number: 10228379
    Abstract: There is provided protein biomarkers and methods for their use in diagnosing and treating Inflammatory Bowel Disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) as well as methods for assessing the severity of the diseases.
    Type: Grant
    Filed: May 28, 2018
    Date of Patent: March 12, 2019
    Assignee: UNIVERSITY OF OTTAWA
    Inventors: Daniel Figeys, Alain Stintzi, David R. Mack, Cheng-Kang Chiang, Amanda Elizabeth Starr
  • Patent number: 10224468
    Abstract: A method of manufacturing a light emitting device includes: arranging first and second light emitting elements, each having a pair of electrodes disposed on a surface opposite to a main light emitting surface, on a base body adjacent to each other with the electrodes facing upward; forming a light shielding member at least covering the electrodes of each of the first and second light emitting elements and a portion between the first and second light emitting elements; forming recesses by removing portions of the light shielding member so that at least a portion of each of the electrodes of the first and second light emitting elements are exposed from the light shielding member; and forming electrically conductive members in the recesses so that each of the electrically conductive members is in contact with a corresponding one of the electrodes of the first and second light emitting elements.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: March 5, 2019
    Assignee: NICHIA CORPORATION
    Inventors: Takahiro Tani, Hiroki Yuu, Toshiaki Moriwaki
  • Patent number: 10209262
    Abstract: Disclosed is a blood sample analyzing method including preparing a measurement specimen by mixing a blood sample with a measuring reagent of fibrin and a fibrinogen degradation product (FDP); acquiring, based on a time-dependent change in optical information obtained by optically measuring the measurement specimen, first information indicating an FDP concentration and second information indicating a curving degree of a time course curve showing the time-dependent change of the optical information; and determining an enhanced fibrinolytic state of the blood sample or acquiring a value related to a D dimer of the blood sample based on the first information and the second information.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: February 19, 2019
    Assignee: SYSMEX CORPORATION
    Inventor: Junki Hayasaki
  • Patent number: 10201617
    Abstract: The present disclosure provides derivatives of 3-substituted piperidine-2, 6-diones, non-covalently bound complexes with serum albumin, pharmaceutical compositions of the same, and methods of use thereof. The non-covalently bound complexes are significantly more water-soluble than the parent compounds, and are useful for the treatment of a cancer, such as multiple myeloma.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: February 12, 2019
    Assignee: Zhuhai Beihai Biotech Co., Ltd.
    Inventor: Qun Sun
  • Patent number: 10202634
    Abstract: Methods for detecting a starch in a sample are provided. The methods include the steps of initially incubating the sample in the presence of an amylase-containing medium and subsequently subjecting the sample to liquid chromatography mass spectrometry (LC-MS) to detect ions characteristic of the starch in the sample. The amylase-containing medium can include an amylase and blood plasma or the amylase-containing medium can include an amylase and a component selected from the group consisting of about 90-92% water or buffered water, about 8% protein, about 0.9% salt, and/or about 1.1% organic substances. The incubating step can be done in conditions that permit digestion of the starch by the amylase.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: February 12, 2019
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Silke Baasner, Frank Nocken, Klaus Biemel
  • Patent number: 10203339
    Abstract: This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: February 12, 2019
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Sven Jacobson
  • Patent number: 10203345
    Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: February 12, 2019
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
  • Patent number: 10196680
    Abstract: The present disclosure relates to methods of identifying target nucleic acids by using coded molecules and its analysis by translocation through a nanopore. Generally, coded molecules are subject to a target polynucleotide dependent modification. The modified coded molecule is detected by isolating the modified coded molecules from the unmodified coded molecules prior to analysis through the nanopore or by detecting a change in the signal pattern of the coded molecule when analyzed through the nanopore.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 5, 2019
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventors: Muhammad A. Sharaf, Timothy Woudenberg, Khairuzzaman Bashar Mullah
  • Patent number: 10196445
    Abstract: The present invention provides anti-CTLA-4 antibodies having enhanced ADCC activity, and their use in treating cancer. In one embodiment, the anti-CTLA-4 antibody is ipilimumab, and ADCC activity is enhanced by introducing G236A, S239D, A330L and I332E mutations (“GASDALIE”) into the Fc region of the heavy chain constant domain.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: February 5, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Engelhardt, Alan J. Korman, Mark J. Selby
  • Patent number: 10190986
    Abstract: A method for analyzing the results of a ligand-receptor binding assay comprising the steps of: (a) providing the results of a ligand-receptor binding assay; and (b) qualifying the results of a ligand-receptor binding assay. More particularly, the ligand-receptor binding assay involves the steps of combining appropriate reagents in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is directly proportional to the amount of ligand present in the sample. Alternatively, the ligand-receptor binding assay involves the steps of combining appropriate reagents to perform a ligand-receptor binding assay in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is inversely proportional to the amount of analyte present in the sample.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: January 29, 2019
    Assignee: Abbott Laboratories
    Inventors: Qiaoqiao Ruan, Sylvia C. Saldana, Joseph P. Skinner, Sergey Y. Tetin
  • Patent number: 10189718
    Abstract: Methods to fabricate tightly packed arrays of nanoparticles are disclosed, without relying on organic ligands or a substrate. In some variations, a method of assembling particles into an array comprises dispersing particles in a liquid solution; introducing a triggerable pH-control substance capable of generating an acid or a base; and triggering the pH-control substance to generate an acid or a base within the liquid solution, thereby titrating the pH. During pH titration, the particle-surface charge magnitude is reduced, causing the particles to assemble into a particle array.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: January 29, 2019
    Assignee: HRL Laboratories, LLC
    Inventors: Adam F. Gross, Shanying Cui, John J. Vajo, Christopher S. Roper
  • Patent number: 10189935
    Abstract: The invention provides new water soluble polymers for the use in industrial processes, where large quantities of water is handled, such as sludge dewatering and papermaking. These new polymers are water soluble cross-linked block copolymers, wherein the block copolymers are cross-linked together using a cross-linking agent. Each of the block copolymers contain two different blocks, and these blocks are formed from different monomers. The blocks are linked together with a molecular spacer derived from a bifunctional initiator used during the polymerization of the blocks. The monomers used in polymerizing the blocks are different with each other and they are selected from a group consisting of N-vinylformamide, acrylic acid, acrylamide and water-soluble derivatives thereof.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: January 29, 2019
    Assignee: KEMIRA OYJ
    Inventors: Asko Karppi, Matti Hietaniemi, Sacha Legrand
  • Patent number: 10190095
    Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: January 29, 2019
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Steven A. Goldman, Neeta Singh Roy, Martha Windrem
  • Patent number: 10190177
    Abstract: The invention provides a rapid, accurate, sensitive, and low-cost detection method for screening a biological sample for one or more desired bacterial species. The inventive method employs a two-step multiplex real-time PCR assay that comprises an internal amplification control and specific primer sets to detect and discriminate bacterial species based the unique melting temperatures of specific DNA sequences of each strain.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: January 29, 2019
    Assignee: The Curators of the University of Missouri
    Inventors: Azlin Mustapha, Prashant Singh
  • Patent number: 10174386
    Abstract: An object of the present invention is to provide a method of quantitating or detecting a microorganism, capable of detecting a live microorganism at high sensitivity and more precisely. A method of quantitating a microorganism of interest, using as an index the amount of rRNA of the microorganism of interest is provided.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: January 8, 2019
    Assignee: KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Hirokazu Tsuji, Kazunori Matsuda, Takashi Asahara, Koji Nomoto, Mayumi Kiwaki
  • Patent number: 10175233
    Abstract: Biomarkers relating to cardiovascular disease, including atherosclerosis and cardiomyopathy, are provided, as well as methods for using such biomarkers as biomarkers for cardiovascular disease. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for cardiovascular disease, including atherosclerosis and cardiomyopathy.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: January 8, 2019
    Assignee: METABOLON, INC.
    Inventors: Yun Fu Hu, Costel Chirila, Danny Alexander, Michael Milburn, Matthew W. Mitchell, Walter Gall, Kay A. Lawton
  • Patent number: 10175252
    Abstract: Method of diagnosis of IVF viability. The method includes ascertaining a subject's AMH level from testing and then selecting one pregnancy or live birth prognosis category that applies to the ascertained AMH level by matching the ascertained AMH level with an applicable one of a plurality of ranges of AMH levels pertaining to an age of the subject. The matching indicates the prognosis category that applies, i.e., (that is, good, intermediate or poor. In view of the diagnosis, a method of administration of AMH may be pursued to increase probability of pregnancy or live birth chances. Alternatively, the administration of AMH may be at AMH levels that will terminate pregnancy or increase the chance of miscarriage.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: January 8, 2019
    Assignee: American Infertility of New York, P.C.
    Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
  • Patent number: 10168326
    Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 1, 2019
    Assignee: F. HOFFMANN-LA ROCHE INC.
    Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel
  • Patent number: 10167574
    Abstract: Embodiments described herein generally relate to biomedical devices including a porous layer forming a support structure for a biological probe and methods of making the same. The porous layer can be a porous silicon containing layer. The pore size can be adjusted such that various size biological probes can be incorporated into the pores. Further, the porous silicon containing layer can be used to support a biofunctionalizing layer.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 1, 2019
    Assignee: Applied Materials, Inc.
    Inventors: Sangmin Jeong, Hann-Ching Chao, Ludovic Godet
  • Patent number: 10161929
    Abstract: Theranostics platforms for identifying drugs and nutraceuticals for treatment of rare disease are described. The platforms comprise (a) a cell-phenotype image-enhancing instrument; (b) a drug/nutraceutical library; and (c) a computer-implemented system for analyzing a response of an optically-visible rare-disease cell phenotype to a drug or nutraceutical from the drug/nutraceutical library.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: December 25, 2018
    Assignee: Sanford Burnham Prebys Medical Discovery
    Inventors: Michael Jackson, Anne Bang
  • Patent number: 10161935
    Abstract: To provide a test substance measurement method and a test substance measurement kit adapted to improve the accuracy of the measurement of a test substance. A test substance measurement kit includes: fluorescent particles which are modified with a first binding substance having specific bindability to a test substance; non-fluorescent particles which are modified with a second binding substance having no specific bindability to the test substance; and a substrate on which a first metal film to which a third binding substance having specific bindability to the test substance is fixed, and a second metal film to which a fourth binding substance having no bindability to the test substance, but having bindability to the first binding substance is fixed, and which has a smaller thickness than the first metal film are formed.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: December 25, 2018
    Assignee: FUJIFILM Corporation
    Inventors: Nobuhiko Fujiwara, Noriyuki Kasagi, Toshihito Kimura, Kazuhiro Nakamura
  • Patent number: 10161940
    Abstract: The present invention concerns the field of tumor therapeutics and diagnostics. Specifically, it relates to a peptide comprising at least 8 amino acids in length which are present as contiguous amino acid sequence in the human Isocitratdehydrogenase Type 1 (IDH1), wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132, for use in preventing and/or treating cancer. Further contemplated is a medicament comprising the said peptide.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: December 25, 2018
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERISTAET HEIDELBERG
    Inventors: Michael Platten, Theresa Bunse, Wolfgang Wick
  • Patent number: 10150807
    Abstract: Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 11, 2018
    Assignee: National Research Council of Canada
    Inventor: Jamshid Tanha
  • Patent number: 10152702
    Abstract: Apparatus and methods are provided for analyzing a medical condition of a user. The apparatus may include a user interface configured to receive user identification information inputted by the user, an analyzer, and a processor all disposed within a common housing. The analyzer is configured to receive a biological specimen from the user and to analyze the biological specimen to generate analysis information. The processor is configured to store and forward the analysis information and to receive prescription information. The apparatus may include a communication unit configured to transmit the user identification information and the analysis information to a doctor at a remote location for review and to receive the prescription information from the doctor. The apparatus then may dispense the prescribed medication or print a medication prescription.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: December 11, 2018
    Inventor: Michael Ingber
  • Patent number: 10150814
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 11, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Paul R. Hinton, Veronica Juan
  • Patent number: 10149823
    Abstract: A respirable dry powder can include acetylsalicylic acid or a pharmaceutically acceptable salt thereof. The dry powder can include a mixture of: (i) dry particles have a volume median geometric diameter (VMGD) less than 5 ?m; and (ii) dry particles have a volume median geometric diameter (VMGD) of about 15 ?m or more.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: December 11, 2018
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • Patent number: 10144767
    Abstract: Antimicrobial peptides and methods of use are provided.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: December 4, 2018
    Assignee: Board of Regents of the University of Nebraska
    Inventor: Guangshun Wang